2,4-二乙基-5-甲基-噻唑 | 52414-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,4-二乙基-5-甲基-噻唑
• 英文名称: 2,4-Diaethyl-5-methyl-thiazol
• 英文别名: 2,4-Diethyl-5-methylthiazole；2,4-diethyl-5-methyl-1,3-thiazole
• CAS: 52414-89-8
• 化学式: C₈H₁₃NS
• 分子量: 155.264
• InChiKey: IFFHSVJYMHLVLT-UHFFFAOYSA-N

物化性质

• 沸点：
  52-53 °C(Press: 1 Torr)
• 密度：
  1.007±0.06 g/cm3(Predicted)
• 保留指数：
  1131

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,4-Diaethyl-5-methyl-thiazolin-Δ³ 在 sulfur 作用下， 生成 2,4-二乙基-5-甲基-噻唑
  参考文献：
  名称：

  Asinger et al., Justus Liebigs Annalen der Chemie, 1957, vol. 610, p. 30

  摘要：

  DOI：

文献信息

• NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Boléa Christelle

  公开号：US20100144756A1

  公开（公告）日：2010-06-10

  The present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , Y 4 , M 1 , M 2 , M 3 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及式（I）的新化合物，其中X1、X2、X3、X4、Y1、Y2、Y3、Y4、M1、M2、M3、Am和Bn如式（I）中所定义；该发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，对于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病具有用处。 该发明还涉及制药组合物以及利用这些化合物制造药物的用途，以及利用这些化合物预防和治疗mGluR4参与的疾病的用途。
• Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
  申请人：Boléa Christelle

  公开号：US20120329811A1

  公开（公告）日：2012-12-27

  The present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , Y 4 , M 1 , M 2 , M 3 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及式（I）的新化合物，其中X1、X2、X3、X4、Y1、Y2、Y3、Y4、M1、M2、M3、A和Bn如式（I）中所定义的；发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物和使用这些化合物制造药物的用途，以及使用这些化合物预防和治疗涉及mGluR4的疾病的用途。
• HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
  申请人：Bunnage Mark Edward

  公开号：US20130196952A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物，以及用于制备含有这些衍生物的组合物的中间体的制备过程和使用。根据本发明的化合物在许多与ALK蛋白有关或抑制ALK活性可能产生益处的疾病中非常有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• US8916593B2
  申请人：——

  公开号：US8916593B2

  公开（公告）日：2014-12-23
• Asinger et al., Justus Liebigs Annalen der Chemie, 1957, vol. 610, p. 30
  作者：Asinger et al.

  DOI：——

  日期：——

表征谱图